Thomas Sweeney Heard

Array ( [id] => 16735654 [patent_doc_number] => 10961290 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Stabilized BCL9 peptides for treatment of aberrant WNT signaling [patent_app_type] => utility [patent_app_number] => 15/766268 [patent_app_country] => US [patent_app_date] => 2016-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 102 [patent_no_of_words] => 34601 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11395171 [patent_doc_number] => 20170015706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'PROLINE COMPOUNDS AS GRANZYME B INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/280953 [patent_app_country] => US [patent_app_date] => 2016-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 32786 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15280953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11395172 [patent_doc_number] => 20170015707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'COVALENT GRANZYME B INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/280969 [patent_app_country] => US [patent_app_date] => 2016-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 27583 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15280969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17489308 [patent_doc_number] => 11278589 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-22 [patent_title] => Use of a cyclic tripeptide for improving cellular energy metabolism [patent_app_type] => utility [patent_app_number] => 15/761825 [patent_app_country] => US [patent_app_date] => 2016-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 8577 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15761825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11663494 [patent_doc_number] => 20170152213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-01 [patent_title] => 'AMINE-CONTAINING LIPIDOIDS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/264315 [patent_app_country] => US [patent_app_date] => 2016-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 24666 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15264315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11335495 [patent_doc_number] => 20160361250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'ACTIVE INGREDIENTS STIMULATING TYPE 2 AND/OR TYPE 3 HUMAN BETA-DEFENSINS AND COSMETIC OR PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH ACTIVE INGREDIENTS' [patent_app_type] => utility [patent_app_number] => 15/248195 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9314 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15248195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11441941 [patent_doc_number] => 20170042961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'METHODS FOR TREATING HCV' [patent_app_type] => utility [patent_app_number] => 15/244926 [patent_app_country] => US [patent_app_date] => 2016-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48906 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15244926 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11323759 [patent_doc_number] => 20160354370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => 'METHOD FOR TREATING A PROTOZOAL INFECTION' [patent_app_type] => utility [patent_app_number] => 15/241308 [patent_app_country] => US [patent_app_date] => 2016-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 30751 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15241308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311703 [patent_doc_number] => 20160347813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'GLUCAGON ANALOGUES' [patent_app_type] => utility [patent_app_number] => 15/239154 [patent_app_country] => US [patent_app_date] => 2016-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12003 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15239154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383659 [patent_doc_number] => 20180243371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => MUSSEL ADHESIVE PROTEIN PRODUCT AND USE THEREOF FOR TREATING MUCOSAL INFLAMMATION [patent_app_type] => utility [patent_app_number] => 15/751551 [patent_app_country] => US [patent_app_date] => 2016-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13078 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443201 [patent_doc_number] => 20170044222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'Anti-Microbial Coatings and Devices' [patent_app_type] => utility [patent_app_number] => 15/235778 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 12694 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15235778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11434712 [patent_doc_number] => 20170035734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'PAR4 INHIBITOR THERAPY FOR PATIENTS WITH PAR4 POLYMORPHISM' [patent_app_type] => utility [patent_app_number] => 15/226425 [patent_app_country] => US [patent_app_date] => 2016-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 18557 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15226425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14452471 [patent_doc_number] => 10322182 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-18 [patent_title] => Lyophilized preparation of cytotoxic dipeptides [patent_app_type] => utility [patent_app_number] => 15/225323 [patent_app_country] => US [patent_app_date] => 2016-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 23 [patent_no_of_words] => 13932 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15225323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11128001 [patent_doc_number] => 20160324975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'REVERSIBLE PEGYLATED DRUGS' [patent_app_type] => utility [patent_app_number] => 15/216870 [patent_app_country] => US [patent_app_date] => 2016-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 37381 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15216870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16696691 [patent_doc_number] => 10947272 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => BACE1 inhibitor peptides [patent_app_type] => utility [patent_app_number] => 15/735394 [patent_app_country] => US [patent_app_date] => 2016-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6058 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15735394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13805085 [patent_doc_number] => 10179804 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-15 [patent_title] => Melanocortin receptor-specific peptides [patent_app_type] => utility [patent_app_number] => 15/214845 [patent_app_country] => US [patent_app_date] => 2016-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 26391 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15214845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11627275 [patent_doc_number] => 20170137463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'HCV PROTEASE INHIBITORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/202501 [patent_app_country] => US [patent_app_date] => 2016-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 39181 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15202501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808693 [patent_doc_number] => 20180161401 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => Novel Formulations of PTHrP Analogue [patent_app_type] => utility [patent_app_number] => 15/579589 [patent_app_country] => US [patent_app_date] => 2016-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107583 [patent_doc_number] => 20160304554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/198152 [patent_app_country] => US [patent_app_date] => 2016-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3338 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15198152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13672499 [patent_doc_number] => 20160374983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => COMBINATION OF ROCAGLAMIDE AND APOPTOSIS INDUCING SUBSTANCES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/196973 [patent_app_country] => US [patent_app_date] => 2016-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15196973 [rel_patent_id] =>[rel_patent_doc_number] =>)